Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Ongoing treatment with metformin on a stable dose of ≥1500 mg/day for at least 12 weeks prior to enrolment~* Inadequate glycemic control, defined as HbA1c ≥6.5% and ≤8.5%~* ≥30 years for males~* ≥55 years for females~Exclusion Criteria:~* Type 1 Diabetes~* Body weight change \>5% within 3 months prior to enrolment~* Renal and liver impairment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Dapagliflozin 10 mg plus Metformin
- B (Type: PLACEBO_COMPARATOR): Placebo plus Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).